This study reveals the non-canonical expression mechanism of CD19 in T cells and myeloid cells, suggesting that the target cell scope must be redefined when evaluating B cell-depleting therapies, offering direct guidance for therapeutic strategy design in autoimmune diseases.
Literature Overview
This paper, 'B cell CD19 is transferred between immune cells in mice and humans,' published in Nature Communications, systematically investigates the phenomenon of the classical B cell marker CD19 being expressed in T cells and myeloid cells through intercellular membrane transfer. The study reveals that this transfer not only alters surface markers of recipient cells but also confers B cell-like functional properties, challenging the specificity principle of traditional immune phenotyping. Further analysis shows that this process occurs via two mechanisms—trogocytosis and efferocytosis—and affects the target spectrum of current anti-CD19 monoclonal antibodies (e.g., inebilizumab), indicating that target cell populations need to be re-evaluated in clinical monitoring.Background Knowledge
The study addresses critical issues in multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). The current bottleneck in CD19 research lies in its classification as a B cell-specific target, overlooking its dynamic expression on other immune cells. The research question centers on whether lateral transfer of membrane proteins during interactions between B cells and T cells or phagocytes could lead to phenotypic confusion. By systematically tracing the origin of CD19 expression, the authors demonstrate that it is not endogenously expressed but acquired through intercellular contact. This finding is crucial for understanding aberrant immune activation mechanisms in autoimmune diseases and provides a novel explanation for off-target effects of B cell-depleting therapies. Furthermore, the co-transfer of molecules such as CD20, IgM, and MHC II suggests that modular transfer of functional units may be widespread, impacting cell clustering strategies based on surface markers.
Research Methods and Experiments
The authors employed transgenic mouse models (e.g., 2D2, OTII, CD19-cre, μMT) in co-culture systems with wild-type mouse splenocytes, combined with antigen-specific T-B cell activation models, to verify the condition-dependent nature of CD19 transfer. Using multidimensional techniques including flow cytometry, membrane dye tracking, confocal microscopy, and RNA-seq, they confirmed that CD19 acquisition is exogenous rather than endogenous. In human samples, co-culture experiments with PBMCs from healthy individuals and patients with MS or NMOSD, stimulated with SEB, validated cross-species conservation. Additionally, using bone marrow-derived macrophages (BMDMs), primary microglia, and iPSC-derived microglia models, along with co-incubation experiments with apoptotic B cells, the study revealed the efferocytosis-mediated mechanism of CD19 transfer. Key evidence includes: co-transfer of CD19 signal with membrane dyes, absence of CD19+ T cells in CD19-cre and μMT mice, RNA-seq showing no CD19 transcripts in T cells, transwell experiments demonstrating contact dependency, and inhibition of transfer by anti-MHC II blocking—all systematically supporting the trogocytosis mechanism.Key Conclusions and Perspectives
Research Significance and Prospects
From a research perspective, this discovery has profound implications for drug development, suggesting that CD19-targeted therapies may not only eliminate B cells but also modulate T cells and phagocytes that have acquired functional properties, potentially enhancing efficacy or introducing new side effects. In clinical monitoring, the potential of CD19+ non-B cell populations as biomarkers of disease activity needs to be re-evaluated. For disease modeling, this study supports the use of more complex co-culture systems or humanized models to simulate intercellular interactions, enabling a more accurate representation of the in vivo immune environment.
Conclusion
This study fundamentally challenges the traditional notion of immune cell marker specificity, revealing that CD19 can be transferred between immune cells via trogocytosis and efferocytosis, enabling T cells and myeloid cells to acquire B cell-like functions. This phenomenon not only explains the high efficacy of anti-CD19 therapy in NMOSD but also suggests that such therapies may exert broader immunomodulatory effects by eliminating 'activated' T cells and phagocytes. From bench to bedside, this finding calls for consideration of acquired CD19 expression on non-B cells when designing and evaluating B cell-targeted therapies, advancing the development of precision immune monitoring. Moreover, the dynamic transfer of CD19 opens new avenues for developing novel bifunctional cell therapies or interventions targeting intercellular communication, with the potential to reshape the care system for autoimmune diseases and serve as a cornerstone for future translational research.
